What is Claimed is:

1. An engineered Gram-negative bacterium for the production of a polysaccharide, wherein the Gram-negative bacterium comprises (a) a nucleic acid encoding a regulatory gene *wzg*, *wzh*, *wzd* or *wze* of a capsular polysaccharide gene cluster of *S. pneumoniae* CPS1, CPS2, CPS3, CPS4, CPS5, CPS6 (A and B), CPS7 (A,B, C), CPS8, CPS9 (A, L,N, V), CPS10 (A,B,C,F), CPS11 (A, B,C,D,F), CPS12(A,B,F), CPS13, CPS14 CPS15(A,B,C,F), CPS16(A,F), CPS17(A,F), CPS18(A,B,C,F), CPS19(A,B,C,F), CPS20,CPS21, CPS22(A,F), CPS23(A,B,F), CPS24(A,B,F), CPS25(A,F), CPS26, CPS27,CPS28(A,F), CPS29, CPS31, CPS32(A,F), CPS33(A,B,C,D,F), CPS34, CPS35(A,B,C,D,F), CPS36, CPS37, CPS38, CPS39, CPS40, CPS41(A,F), CPS42, CPS43, CPS44, CPS45, CPS46, CPS47(A,F), or CPS48; (b) a nucleic acid encoding a regulatory gene *capA*, *capB* or *capC* of a capsular polysaccharide gene cluster of *Staphylococcus aureus* CPS5, or CPS8; or (c) a nucleic acid encoding a regulatory gene CpsA, CpsB, CpsC or CpsD of a capsular polysaccharide gene cluster of *Streptococcus agalactiae* (group B, GBS) CPSIa, CPSIb, CPSII, CPSIII, CPSIV, CPSV, CPSVI, CPSVII, or CPSVIII; wherein the Gram-negative bacterium further comprises an oligosaccharyl transferase which is heterologous to the Gram-negative bacterium.

2. The Gram-negative bacterium of claim 1, wherein the Gram-negative bacterium comprises at least 25%, 50%, 75%, 85%, 90%, or at least 95% of the open reading frames of the capsular polysaccharide gene cluster.

3. The Gram-negative bacterium of claim 1, wherein said Gram-negative bacterium is selected from the group consisting of *Escherichia* species, *E. coli*, *Shigella* species, *Klebsiella* species, *Salmonella* species, *Yersinia* species, *Neisseria* species, *Vibrio* species and *Pseudomonas* species.

4. The Gram-negative bacterium of any one of the preceding claims, wherein said regulatory gene is a *Streptococcus pneumoniae* regulatory gene.

5. The Gram-negative bacterium of claim 4, wherein said regulatory gene is from *S. pneumoniae* Type 1 or *S. pneumoniae* Type 4.

6. The Gram-negative bacterium of any one of claims 1-3, wherein said regulatory gene is a *Staphylococcus aureus* regulatory gene.

7. The Gram-negative bacterium of any one of claims 1-3, wherein said regulatory gene is a *Streptococcus agalactiae* regulatory gene.

8. The Gram-negative bacterium of any one of the preceding claims, wherein one or more genes native to the Gram-negative bacterium have been deleted or inactivated.

9. The Gram-negative bacterium of claim 8, wherein the *waaL* gene has been deleted.

10. The Gram-negative bacterium of claim 9, wherein all genes associated with O antigen biosynthesis in the Gram-negative bacterium have been deleted.

11. The Gram-negative bacterium of any one of the preceding claims, wherein said regulatory gene is *wzg*, *wzh*, *wzd*, *wze*, *capA*, *capB*, or *capC*.

12. The Gram-negative bacterium of any one of the preceding claims, further comprising a nucleic acid encoding a carrier protein comprising a consensus sequence for glycosylation.

13. The Gram-negative bacterium of claim 12 wherein the carrier protein comprising a consensus sequence for glycosylation is heterologous to the Gram-negative bacterium.

14. The Gram-negative bacterium of claim 12 wherein the carrier protein comprising a consensus sequence for glycosylation is detoxified exotoxin A from *P. aeruginosa*, CRM197, Diphtheria toxoid, tetanus toxoid, detoxified hemolysin A of *S. aureus*, clumping factor A, clumping factor B, *E. coli* FimH, *E. coli* FimHC, *E. coli* heat labile enterotoxin, detoxified variants of *E. coli* heat labile enterotoxin, Cholera toxin B subunit (CTB), cholera toxin, detoxified variants of cholera toxin, *E. coli* sat protein, the passenger domain of *E. coli* sat protein, *C. jejuni* AcrA, *C. jejuni* natural glycoproteins, *S. pneumoniae* pneumolysin, *S. pneumoniae* NOX, *S. pneumoniae* PspA, *S. pneumoniae* PcpA, *S. pneumoniae* PhtD, *S. pneumoniae* PhtE, *S. pneumoniae* Ply, or *S. pneumoniae* LytB.

15. A recombinant glycoprotein produced by the Gram-negative bacterium of any one of claims 1-14, wherein the recombinant glycoprotein comprises a capsular polysaccharide selected from *S. pneumoniae* CPS1, CPS2, CPS3, CPS4, CPS5, CPS6 (A and B), CPS7 (A,B, C), CPS8, CPS9 (A, L,N, V), CPS10 (A,B,C,F), CPS11 (A, B,C,D,F), CPS12(A,B,F), CPS13, CPS14 CPS15(A,B,C,F), CPS16(A,F), CPS17(A,F), CPS18(A,B,C,F), CPS19(A,B,C,F), CPS20,CPS21, CPS22(A,F), CPS23(A,B,F), CPS24(A,B,F), CPS25(A,F), CPS26, CPS27,CPS28(A,F), CPS29, CPS31, CPS32(A,F), CPS33(A,B,C,D,F), CPS34, CPS35(A,B,C,D,F), CPS36, CPS37, CPS38, CPS39, CPS40, CPS41(A,F), CPS42, CPS43, CPS44, CPS45, CPS46, CPS47(A,F), or CPS48; or *Staphylococcus aureus* CPS5, or CPS8; or *Streptococcus agalactiae* (group B, GBS) CPSIa, CPSIb, CPSII, CPSIII, CPSIV, CPSV, CPSVI, CPSVII, or CPSVIII.

16. A method of producing a recombinant glycoprotein comprising culturing the Gram-negative bacterium of any one of claims 1-14 under conditions suitable for the production of the recombinant glycoprotein, wherein the recombinant glycoprotein comprises a capsular polysaccharide selected from *S. pneumoniae* CPS1, CPS2, CPS3, CPS4, CPS5, CPS6 (A and B), CPS7 (A,B, C), CPS8, CPS9 (A, L,N, V), CPS10 (A,B,C,F), CPS11 (A, B,C,D,F), CPS12(A,B,F), CPS13, CPS14 CPS15(A,B,C,F), CPS16(A,F), CPS17(A,F), CPS18(A,B,C,F), CPS19(A,B,C,F), CPS20,CPS21, CPS22(A,F), CPS23(A,B,F), CPS24(A,B,F), CPS25(A,F), CPS26, CPS27,CPS28(A,F), CPS29, CPS31, CPS32(A,F), CPS33(A,B,C,D,F), CPS34, CPS35(A,B,C,D,F), CPS36, CPS37, CPS38, CPS39, CPS40, CPS41(A,F), CPS42, CPS43, CPS44, CPS45, CPS46, CPS47(A,F), or CPS48; or *Staphylococcus aureus* CPS5, or CPS8; or *Streptococcus agalactiae* (group B, GBS) CPSIa, CPSIb, CPSII, CPSIII, CPSIV, CPSV, CPSVI, CPSVII, or CPSVIII.

17. A method of producing a recombinant glycoprotein according to claim 16, further comprising purifying the recombinant glycoprotein.

18. A method of producing a glycoconjugate vaccine which comprises pneumococcal polysaccharides, comprising producing recombinant glycoproteins by culturing the Gram-negative bacterium of any one of claims 1-14 under conditions suitable for the production of recombinant glycoproteins, wherein the recombinant glycoproteins comprise capsular polysaccharides selected from *S. pneumoniae* CPS1, CPS2, CPS3, CPS4, CPS5, CPS6 (A and B), CPS7 (A,B,C), CPS8, CPS9 (A,L,N,V), CPS10 (A,B,C,F), CPS11 (A,B,C,D,F), CPS12 (A,B,F), CPS13, CPS14, CPS15 (A,B,C,F), CPS16 (A,F), CPS17 (A,F), CPS18 (A,B,C,F), CPS19 (A,B,C,F), CPS20, CPS21, CPS22 (A,F), CPS23 (A,B,F), CPS24 (A,B,F), CPS25 (A,F), CPS26, CPS27, CPS28 (A,F), CPS29, CPS31, CPS32 (A,F), CPS33 (A,B,C,D,F), CPS34, CPS35 (A,B,C,D,F), CPS36, CPS37, CPS38, CPS39, CPS40, CPS41 (A,F), CPS42, CPS43, CPS44, CPS45, CPS46, CPS47 (A,F), or CPS48.

19. A method of producing a glycoconjugate vaccine according to claim 18 further comprising purifying the recombinant glycoproteins.

20. The method of producing a glycoconjugate vaccine of claim 18 or claim 19 wherein the recombinant glycoproteins comprise capsular polysaccharides selected from *S. pneumoniae* CPS1, CPS4 and CPS14.